PhoreMost and ThinkCyte collaborate to advance AI based drug discovery

New hope in the fight against unmet diseases

15-Dec-2022 - PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, and ThinkCyte K.K, a biotechnology company pioneering novel cell analysis and sorting instruments, announced a strategic research partnership aimed at advancing modern phenotypic drug ...

PhoreMost enters multi-target collaboration with Arvinas

PhoreMost to deploy its SITESEEKER Targeted Protein Degradation platform to enable drug discovery against multiple therapeutic targets

03-Nov-2022 - PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, announced it has entered into a multi-target collaboration with Arvinas, an industry leader in targeted protein degradation (TPD). Under the terms of the agreement, PhoreMost will ...

PhoreMost enters multi-project drug target discovery collaboration with Roche

PhoreMost to deploy its SITESEEKER platform to identify novel targets for Roche’s discovery programmes

07-Sep-2022 - PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, announced it has entered into a multi-project target discovery collaboration with Roche. Under the terms of the agreement, PhoreMost will receive an upfront payment and is eligible for ...

The two startups NeoCura and PhoreMost announce research collaboration to explore novel cancer therapeutics

19-Jan-2022 - NeoCura Bio-Medical Technology Co., Ltd., a RNA-based drug research and development company in China, and PhoreMost Limited, the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’, announced an oncology drug discovery research collaboration As part of the collaboration, ...

PhoreMost and POLARISqb announce a multi-target collaboration to investigate next-generation cancer therapies

Start-ups combine biotechnology and artificial intelligence

06-Jan-2022 - PhoreMost Limited, a UK-based biopharmaceutical company dedicated to developing drugs against intractable disease targets, and Polaris Quantum Biotech (POLARISqb), a NC-based quantum computing drug design company, announced a collaborationto study oncology targets currently considered ...

PhoreMost closes £33M Series B financing

Start-up is advancing its pipeline of novel therapies for oncology and diseases of ageing

25-Mar-2021 - PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, announced it has completed an oversubscribed £33m ($46m) Series B investment round. The round was led by BGF, the UK’s most active growth economy investor, and included new investors ...

Brain inflammation targeted in first drug discovery project from £3m Dementia Consortium

23-Jun-2015 - Funding worth nearly half a million pounds will unite academics at the University of Southampton with drug discovery experts at the medical research charity MRC Technology, to target the immune system in the hunt for new treatments for Alzheimer's disease.The work is the first to be funded by the ...

BioVersys and Enamine Announce Extension of Drug Discovery Collaboration to Address Multidrug-Resistant Bacterial Infections

04-Dec-2014 - Enamine Ltd. and BioVersys AG announced the extension of their drug discovery collaboration for the 4th consecutive year. Since the start of the collaboration Enamine has provided expertise in screening of compounds and chemistry know-how for hit finding activities and optimization. BioVersys has ...

MRC Technology Sells Its Melanocortin Receptors Programme to Pfizer Inc.

Small molecules developed in collaboration with Queen Mary University of London

20-Jun-2014 - MRC Technology, a technology transfer organisation, announced that it has sold to Pfizer Inc. its melanocortin receptors (MCRs) programme, which includes a set of small molecules. Targets for these small molecules came to the attention of MRC Technology from Mauro Perretti, Professor of ...

Almirall and BioFocus enter research alliance

Three-year integrated drug discovery alliance is for identifying drug development candidates for treating respiratory disease

26-Jan-2012 - Almirall, S.A. announced that it has formed a research alliance with BioFocus, an affiliate from Galapagos NV.The three-year alliance is aimed at delivering drug development candidates directed to a key respiratory target of interest to Almirall. Under the terms of the collaboration, BioFocus ...